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Edited by Horst FeldmannAbstract The 2A proteinase (2Apro) of human rhinoviruses
(HRVs) initiates proteolytic processing by cleaving between the
C-terminus of VP1 and its own N-terminus. It subsequently
cleaves the host protein eIF4GI. HRV2 and HRV14 2Apro cleave
at IITTA * GPSD and DIKSY * GLGP on their respective
polyproteins. The HRV2 2Apro cleavage site on eIF4GI is
TLSTR * GPPR. We show that HRV2 2Apro can self-process
at the eIF4GI cleavage sequence whereas HRV14 2Apro cannot,
due to the presence of the arginine residue at P1. The mutations
A104C or A104S in HRV14 2Apro restored cleavage when argi-
nine was present at P1, although not to wild-type levels. These
experiments deﬁne residues which determine substrate recogni-
tion in rhinoviral 2Apro.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Human rhinovirus serotypes1. Introduction
Human rhinoviruses (HRVs) and enteroviruses, members of
the picornavirus family [1], use proteolytic processing to gener-
ate their mature viral proteins from the initial translation
product of viral RNA, the polyprotein [2]. The initial cleavage
event on the polyprotein of these viruses is performed by the
2A proteinase (2Apro, a chymotrypsin-like cysteine proteinase
comprising around 140 amino acids [3,4]. 2Apro cleaves be-
tween the C-terminus of the preceding protein VP1 (viral cap-
sid protein 1) and its own N-terminus [3]. Genetic evidence has
indicated that rhino- as well as enteroviral 2Apro are excellent
targets for anti-viral substances [5].
The crystal structure of 2Apro from HRV2, one of the over
hundred known serotypes, and the solution structure of cox-
sackievirus (CVB4) 2Apro have been determined [6,7]. BothAbbreviations: eIF4G, Eukaryotic initiation factor 4G; HRV, Human
rhinovirus; PAGE, Polyacrylamide gel electrophoresis; RRL, Rabbit
reticulocyte lysate; 2Apro, 2A proteinase; SGPB, Streptomyces griseus
protease B; VP1, Viral capsid protein 1
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the exact interactions of enzyme with substrate for this class
of enzymes remain unclear. Such knowledge would help to im-
prove and further develop the recently described inhibitors of
HRV2 and HRV14 2Apro, zVAD.fmk (benzyloxycarbonyl-
Val-Ala-Asp (OMe)-ﬂuoromethylketone) and zVAM.fmk
(benzyloxycarbonyl-Val-Ala-Met-ﬂuoromethylketone) [8,9].
A further obstacle to inhibitor development is the hetero-
geneity of HRV 2Apro sequences. For example, HRV2 and
HRV14 2Apro share only 40% identity at the amino acid level
[10,11]. In addition, the cleavage sites of these two 2Apro on
their respective polyproteins also diﬀer; the HRV2 2Apro site
is IleIleThrThrAla * GlyProSerAsp whereas that of HRV14
2Apro is AspIleLysSerTyr * GlyLeuGlyPro. Nevertheless, both
enzymes can process the host protein eukaryotic initiation fac-
tor (eIF) 4GI [12,13]. The cleavage site on eIF4GI of HRV2,
poliovirus type 1 and coxsackievirus B4 2Apro has been identi-
ﬁed as LeuSerThrArg * GlyProProArg [14,15] whereas that for
HRV14 2Apro has not yet been determined.
To begin to understand the substrate speciﬁcity of HRV14
2Apro, we wished to investigate whether the eIF4GI sequence
could serve as a substrate in the self-processing reaction of
the HRV2 and HRV14 2Apro.2. Materials and methods
2.1. Plasmids
The plasmid pHRV2 VP1-2Apro encoding HRV2 VP1 and 2Apro
(nucleotides 2318 to 3586) has been described [16]. pHRV14 VP1-
2Apro encodes the HRV14 VP1 and 2Apro (nucleotides 2321 to 3630)
cloned into the pCITE vector. The viral sequences lie downstream of
the encephalomyocarditis virus (EMCV) internal ribosome entry site
in the plasmid pCITE (Novagen).2.2. Site directed mutagenesis
Mutated DNA fragments were obtained either by PCR using mu-
tated primers or by using oligonucleotide cassettes. Restriction enzyme
sites were introduced when required to facilitate the introduction of the
cassettes without changing the amino acid sequences.2.3. In vitro transcription
Plasmids were linearised by restriction with BamHI and puriﬁed by
phenol/chloroform extraction followed by ethanol precipitation. In vi-
tro transcription was for 1.5 h at 37 C; reactions (100 ll) contained
the linearised DNA, 5 mM DTT (Promega), 0.25 mM NTPs (Invitro-
gen), 1· transcription buﬀer (Promega), 120 U of RNasin (Promega)
and 20 U of T7 RNA polymerase (Promega). DNA was removed by
addition of 30 U of DNase I (Invitrogen) and incubation at 37 C
for 20 min. The RNA was puriﬁed by phenol/chloroform extraction
followed by precipitation with ethanol and ammonium acetate. RNA
quality was examined on 1% agarose gels containing 0.1% SDS.blished by Elsevier B.V. All rights reserved.
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In vitro translation reactions (typically 10 ll) contained 70% rabbit
reticulocyte lysate (RRL; Promega), 20 lCi of 35S methionine (1000 Ci/
mmol; Hartmann Analytic), 0.8 U of RNasin/ll and unlabeled amino
acids at 20 lM. The reactions were pre-incubated for 2 min at 30C
and the translations were started by addition of mRNA to a ﬁnal con-
centration of approximately 10 ng/ll. Samples (10ll) were taken at dif-
ferent time points and placed on ice; translation was stopped by
addition of unlabelled methionine and cysteine to a ﬁnal concentration
of 0.4 mM and Laemmli sample buﬀer (40 ll).
2.5. Polyacrylamide gel electrophoresis (PAGE)
The polyacrylamide gel electrophoresis system described by Dasso
and Jackson [17] was used for analysis of the translation products.
The gels contained 17.5% polyacrylamide. Following electrophoresis,
gels were incubated for 30 min in 1 M sodium salicylate (dissolved in
45% methanol) and exposed after drying on Kodak Biomax MR ﬁlm.3. Results
3.1. The eIF4GI cleavage site of HRV2 2Apro is recognised in the
self-processing reaction by HRV2 but not by HRV14 2Apro
Self-processing by HRV2 2Apro can be observed by using
RRLs to translate an in vitro synthesised RNA encoding the
VP1-2Apro precursor [16]. Fig. 1A shows the result of such
an experiment; HRV2 2Apro cleavage reaches 50% completion
at 20 min and is essentially complete at 60 min, as described
[16]. To investigate whether the HRV2 2Apro could recognise
the eIF4GI cleavage site, we replaced the amino acids at either
side of the wild-type cleavage site with those from the eIF4GI
site. The most signiﬁcant diﬀerences are the presence of argi-
nine residues at P1 (instead of alanine) and at P4 0 (instead of
aspartic acid). The exact cleavage sites present in each con-Fig. 1. The eIF4GI cleavage site of HRV2 2Apro is recognised in the self-
incubated with or without 10 ng/ll of the indicated mRNAs as described in S
addition and protein synthesis terminated by addition of unlabeled methionin
protein synthesis and self-processing of 2Apro on 17.5% PAGE followed by
with the eIF4GI cleavage site (TLSTR * GPPR); (C) HRV14 VP1-Apro
(TLSTR * GPPR). The positions of uncleaved HRV VP1-2Apro, and the clea
are shown in both panels.struction are given above the respective ﬂuorogram. Investiga-
tion of the kinetics of the self-processing reaction (Fig. 1B)
shows indeed that the presence of the amino acids from the
eIF4GI cleavage site did aﬀect the rate of self-processing of
HRV2 2Apro. Fifty percent self-processing from the mutated
sequence was not observed until between 30 and 60 min and
cleavage was not complete until after 60 min (Fig. 1B). This
contrasts with the wild-type values of 50% self-processing at
20 min and complete cleavage at 60 min (Fig. 1A). Thus,
although the reaction rate is slowed somewhat, HRV2 2Apro
can tolerate the presence of the eIF4GI cleavage site in the
self-processing reaction.
We then investigated the kinetics of self-processing by
HRV14 2Apro. Fig. 1C shows that the kinetics of self-process-
ing of HRV14 2Apro on its cognate viral polyprotein site are
similar to those of HRV2 2Apro, with 50% cleavage being ob-
served at about 30 min. In contrast to the HRV2 2Apro, how-
ever, the HRV14 2Apro was unable to perform self-processing
when the eIF4GI cleavage site replaced the viral polyprotein
cleavage site (Fig. 1D). The ﬁrst indications of cleavage could
only be seen 180 min after translation had been initiated.3.2. Which residues in the eIF4GI site are responsible for
reducing the eﬃciency of HRV14 2Aproself-processing?
In contrast to the situation with HRV2 2Apro, the eIF4GI
cleavage site diﬀers signiﬁcantly from the HRV14 2Apro se-
quence at P3 (Ser in place of Lys), P1 (Arg in place of Tyr)
as well as P2 0 to P4 0 (ProProArg in place of LeuGlyPro; see
Figs. 1C and D). To investigate which of these substitutions
was responsible for the lack of cleavage of the eIF4GI cleavage
site by the HRV2 2Apro, we began to change the eIF4GI cleav-processing reaction by HRV2 but not by HRV14 2Apro. RRLs were
ection 2. Samples were taken at the indicated time points after mRNA
e and cysteine and Laemmli Sample Buﬀer. Aliquots were analyzed for
ﬂuorography. (A) HRV2 VP1-2Apro wild-type; (B) HRV2 VP1-2Apro
wild-type; (D) HRV14 VP1-2Apro with the eIG4GI cleavage site
vage products VP1 and 2Apro are marked. Protein standards (in kDa)
Fig. 2. HRV14 2Apro cannot accept arginine at the P1 position. RRLs were incubated with or without mRNA (10ng/ll). (A) HRV14 VP1-2Apro with
the eIF4GI cleavage site in which the P1 site was substituted by tyrosine (TLSTY * GPPR); (B) HRV14 VP1 Y289R 2Apro. Analysis of protein
synthesis was as in Fig. 1.
Fig. 3. The structure of HRV2 2Apro. Ribbon diagrams of the overall
structure of HRV2 2Apro. The single a-helix is in green, the b-strands
of the N-terminal and C-terminal domains are in silver and deep blue,
respectively. The three residues of the catalytic triad are shown as are
residues C101 and E102. The drawing was generated using the
program Molscript [20].
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type residues one at a time. Given the importance of the P1 res-
idue in determining speciﬁcity in chymotrypsin-like enzymes,
we started by replacing the P1 arginine with tyrosine.
Fig. 2A shows that this replacement at P1 was suﬃcient to re-
store HRV14 2Apro self-processing activity to essentially wild-
type levels. The band seen at 30 kDa in this experiment is
generated by the RRL itself, as it is also visible in the control
without RNA (Fig. 2A, right lane).
To conﬁrm the importance of the occupancy of the P1 posi-
tion, we then performed the reverse experiment by replacing just
the tyrosine at the P1 site in the wild-type sequence with arginine
(HRV14 VP1 Y289R 2Apro. Fig. 2B shows that HRV14 2Apro-
can no longer process itself from VP1. No cleavage products
were visible even after 7 h, although some non-speciﬁc protein
degradation is visible even after 120 min. In contrast, control
experiments showed that HRV14 2Apro processing was not
aﬀected by the replacement of the P3 lysine residue with the
eIF4GI residue serine nor by replacement of the P2 0 leucine
residue with the eIF4GI residue proline (data not shown).
Taken together, these results show that HRV2 and HRV14
2Apro diﬀer markedly in their speciﬁcity at P1. HRV2 2Apro
can accept arginine at P1 whereas HRV14 2Apro cannot.
3.3. HRV14 2Apro A104 has a role in substrate recognition
Which residues are involved in recognising the P1 amino
acid in HRV 2Apro? At present, only the three-dimensional
structure of HRV2 2Apro is available. Petersen et al. [6] noted
that the side-chain of residue C101 of HRV2 2Apro protrudes
into the site (known as the S1 pocket) on the enzyme recog-
nising the P1 substrate residue (Fig. 3). At the bottom of the
pocket, the carboxylate side-chain of E102 provides a negative
charge, which presumably assists in accepting the positive
charge on the arginine residue at the P1 position.
The equivalent residues in HRV14 2Apro are A104 and E105;
clearly, though, the presence of glutamic acid at residue 105 is
not suﬃcient for recognition of arginine at P1. We wondered
therefore whether replacement of A104 with cysteine might im-
prove the activity of HRV14 2Apro on a substrate with arginine
at P1. This idea was strengthened by analysis of the 2Apro
sequences of other picornaviruses. The analysis revealed a
certain consistency between the residue present at the P1 site
and that at position 101 (using the HRV2 2Apronumbering)
in the enzyme. Of the eight genetic group A human rhinovi-
ruses for which 2Apro sequence data is available, four (sero-types 2, 39, 54 and 85) have an alanine at P1 and four have
valine (serotypes 1B, 9, 16, 89); all of them show a cysteine
at residue 101 or its equivalent. The sequences of seven genetic
group B human rhinoviruses have tyrosine at P1 and alanine at
the equivalent of residue 101 (B. Holzer, pers. comm.). The
three poliovirus serotypes also have a tyrosine at the P1 site
and an alanine at the position equivalent to residue 101. Cox-
sackievirus serotypes B1, B3, B4, B5 and B6 all have a threo-
nine at P1 and a serine residue at the equivalent residue of the
101 residue, respectively. Table 1 summarises the residues
found at the P1 site and at residue 101 or its equivalent.
Based on the structural data and the sequence comparisons,
we replaced A104 in the P1 tyrosine to arginine (HRV14 VP1
Y289R 2Apro mutant with cysteine and serine. Fig. 4 shows
that the activity of the proteinase is partially recovered, with
the cleavage product VP1 being observed after 60 min in both
Table 1
Occupancy of the P1 residue of the 2Apro cleavage site and residue 101 or its equivalent of 2Apro
Virus Cleavage site Active site 
----------VP1---------><---------------------------2Apro--------------------------------------------->
P1 101 106
HRV 2 .....TRPIITTA * GPSDMYV7............... 97GEGPCEPGDCGGKL110....142
HRV89 .....DVFTVTNV * GPSSMFV7............... 97GEGPCEPGDCGGKL110....142
(genetic group A) 
HRV14 .....RKGDIKSY * GLGPRYG7...............100GVGPAEPGDCGGIL113....146
(genetic group B) 
Poliovirus type 1 .....STKDLTTY * GFGHQNK7...............100GHGFASPGDCGGIL113....149
Coxsackievirus B4 .....ERASLITT * GPYGHQS7...............101ATGFSEPGDCGGIL114....150
The P1 and 101 or equivalent residues are shown in bold face. The active site residue cysteine (residue 106 in HRV2 2Apro) is underlined. The
sequence identiﬁers are: POLG_HRV2, POLG_HRV89, POLG_HRV14, POLG_POL1M and POLG_CXB4J.
Fig. 4. Substitution of HRV14 2Apro A104 can partially restore self-processing on the mutant HRV14 VP1 Y289R 2Apro. RRLs were incubated with
or without mRNA (10 ng/ll). (A) HRV14 VP1 Y289R 2Apro A104C; (B) HRV14 VP1 Y289R 2Apro A104S. Analysis of protein synthesis was as in
Fig. 1.
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cient, as more speciﬁc product is visible at the 120, 180 and
300 min time-points than with cysteine 104 mutant. The insta-
bility of the uncleaved precursors prevents however an exact
quantization of the levels of uncleaved precursors and thus
the absolute extent of cleavage observed.4. Discussion
An understanding of the substrate speciﬁcity of rhino- and
enteroviral 2Apro is essential for the development of eﬀective
inhibitors. In the absence of structures for these enzymes
bound to either substrates or inhibitors, we modulated the
speciﬁcity by site-directed mutagenesis based on amino acid se-
quence comparisons and the crystal structure of HRV2 2Apro
alone. We show here a clear diﬀerence in the recognition of
the P1 substrate residue by HRV2 and HRV14 2Apro. HRV2
2Apro could eﬃciently carry out self-processing when thewild-type cleavage site was replaced by that of eIF4GI. In
contrast, HRV14 2Apro could not.
Site-directed mutagenesis experiments showed that the pres-
ence of arginine at P1 was responsible for the lack of cleavage
by HRV14 2Apro. Furthermore, HRV14 2Apro could not rec-
ognise arginine at P1 when introduced into the wild-type cleav-
age site. Previous work on the substrate speciﬁcity of HRV14
2Apro was limited to the cleavage of oligopeptides [18]. Curi-
ously, HRV14 2Apro was poorly active on a peptide corre-
sponding to its wild-type cleavage site. An improvement was
observed when peptides corresponding to the HRV2 2Apro
wild-type or eIF4GI cleavage sites were employed. However,
as in both cases the P1 tyrosine of the HRV14 2Apro wild-type
sequence site was retained, these data shed no light on the
speciﬁcity of HRV14 at the P1 position. It will be important
to determine the cleavage site of HRV14 and other genetic
group B HRVs on eIF4GI to see whether the same site is used
as that by the 2Apro of genetic group A HRVs, poliovirus sero-
type 1 and coxsackievirus B4.
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at P1 by HRV14 2Apro was achieved by substituting residue
alanine 104 with either cysteine or serine. However, the rate
of self-processing obtained on the mutated cleavage site re-
mained substantially lower from that observed with the
HRV14 2Apro on the wild-type cleavage site. Clearly, other res-
idues are involved in the recognition of the P1 residue, but,
given the low level of identity between HRV2 and HRV14
2Apro, it will only be possible to identify such residues when
the crystal structure of HRV14 2Apro becomes available.
The most closely related serine proteinase to picornaviral
2Apro is Streptomyces griseus proteinase B (SGPB). Interest-
ingly, the equivalent residues to A104 and E105 of HRV14
2Apro and C101 and E102 of HRV2 2Apro are alanine 192
and glutamic acid 192A [19]. Indeed, these residues of SGPB
superimpose well on those of HRV2 2Apro. The constellation
of alanine 192 and glutamic acid 192A in SGPB, if analogous
to the situation in HRV14, would imply that SGPB would pre-
fer tyrosine over arginine at the P1 position. Bateman et al. [19]
determined the P1 preference of this enzyme using variants of
the third domain turkey ovomucoid inhibitor of serine protein-
ases and found that an inhibitor with tyrosine at the P1 posi-
tion bound ten to twenty fold more strongly to SGPB than did
a mutant inhibitor with arginine at P1. Thus, the speciﬁcity of
SGPB supports the role of A104 in the speciﬁcity of HRV14
2Apro, but once again, the low level of overall similarity
between SGPB and HRV14 2Apro precludes identiﬁcation of
other residues involved in recognising the P1 residue in
HRV14 2Apro. It would be of interest to replace A192 with
cysteine in SGPB and observe the eﬀect on the binding of
the turkey ovomucoid inhibitor mutants.
In summary, we have shown that the speciﬁcity of HRV2
2Apro and HRV14 2Apro diﬀer signiﬁcantly at the P1 position.
It will be necessary to take these diﬀerences into account when
designing inhibitors. Furthermore, it will be of interest to
examine whether these diﬀerences are responsible for cleavage
of diﬀerent host proteins in the infected cell and consequently
for diﬀerences in the pathogenicity of viruses from the two
genetic groups.
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